Amylyx Pharmaceuticals Inc.

Amylyx Pharmaceuticals Inc. Ushering in a new era for treating diseases with high unmet needs

This week, is at the Wolfram Syndrome UK’s International Researcher’s Symposium, where we’re presenting updates on our...
06/02/2026

This week, is at the Wolfram Syndrome UK’s International Researcher’s Symposium, where we’re presenting updates on our Phase 2 HELIOS trial in Wolfram syndrome. More details below.

In recognition of Mental Health Awareness Month, we took time to step away from Anchor Week updates and recharge with ha...
05/29/2026

In recognition of Mental Health Awareness Month, we took time to step away from Anchor Week updates and recharge with hands-on, creative activities. These are the moments that help strengthen our community and support a culture of care.

05/22/2026

Wolfram syndrome is a rare genetic disorder that affects approximately 3,000 people living in the U.S. with no approved treatment options.

Common manifestations of Wolfram syndrome include insulin-requiring diabetes mellitus, vision loss, diabetes insipidus, hearing loss, neurogenic bladder, impaired balance and coordination, and difficulty breathing that can progress to respiratory failure. Learn more about Wolfram syndrome on our website at https://www.amylyx.com/

05/15/2026

We’re pleased to share that Week 24 and Week 48 results from our Phase 2 open-label HELIOS clinical trial in Wolfram syndrome have been published in the Journal of Clinical Investigation. These findings indicate continued improvement in pancreatic function and visual acuity stabilization over 48 weeks, as well as a generally well-tolerated safety profile. Read more in today’s release: https://www.amylyx.com/news/amylyx-pharmaceuticals-announces-peer-reviewed-publication-of-phase-2-open-label-helios-trial-data-for-amx0035-in-the-journal-of-clinical-investigation

05/12/2026

Calpain-2 (CAPN2) is an important contributor to axonal degeneration, or nerve fiber damage, which plays a critical role in ALS progression.

Research suggests that when calpain-2 becomes overactive, it can interfere with normal cell function and weaken the nerve fibers that carry signals throughout the body.

Learn more about the connection between calpain-2 and ALS on our website at https://bit.ly/4u9G3J5

05/05/2026

We’re pleased to announce the launch of a U.S. expanded access program (EAP) for post-bariatric hypoglycemia (PBH). See today’s press release for more information: https://bit.ly/42LEzZh

Additional information about the EAP is available at amylyx.com/global-access-policy.

04/29/2026

Post-bariatric hypoglycemia (PBH) is a rare, chronic condition with no FDA-approved treatments. Among the roughly two million people who have had Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy in the past decade in the U.S., an estimated 160,000 are living with PBH today.

The condition can cause debilitating low blood sugar episodes when the brain does not receive enough glucose. PBH can be difficult to diagnose as symptoms, such as brain fog, fatigue, sweating, blurred vision, and dizziness, can be non-specific, vary in severity, and/or be mistaken for dumping syndrome. Learn more about PBH on our website at https://bit.ly/4cCeodq

What we’re doing, why, and how we’re doing it is deeply interwoven. Learn more about one of our five core values guiding...
04/24/2026

What we’re doing, why, and how we’re doing it is deeply interwoven. Learn more about one of our five core values guiding Rob Chang and the rest of below.

This week, is at the American Association of Clinical Endocrinology’s (AACE) Annual Meeting in Las Vegas. More details...
04/22/2026

This week, is at the American Association of Clinical Endocrinology’s (AACE) Annual Meeting in Las Vegas. More details below. We hope to see you there!

04/17/2026

After Maggie was diagnosed with post-bariatric hypoglycemia (PBH), she had trouble finding answers for living with this condition, adding another difficult layer to managing her often debilitating symptoms.

We created the “Understanding PBH” guide to provide education, support, and a sense of connection for the PBH community. Learn more about PBH through Maggie’s story and explore the guide here: https://bit.ly/4cid8vP

Address

55 Cambridge Parkway, Suite 6W
Cambridge, MA
02142

Website

https://www.amylyx.com/social-media-guidelines, https://www.amylyx.com/privacy-notice

Alerts

Be the first to know and let us send you an email when Amylyx Pharmaceuticals Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share